<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763865</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00033680</org_study_id>
    <nct_id>NCT02763865</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor</brief_title>
  <official_title>A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Low Frequency Repetitive
      Transcranial Magnetic Stimulation (LF r-TMS) of the pre-Supplementary Motor Area (pre-SMA) on
      tremor as measured by the tremor rating scale (TRS) in patients with Essential Tremor (ET).

      Hypothesis: Pre-SMA LF r-TMS will result in a &gt;30% reduction in tremor as measured by the
      TRS. Another purpose of this study is to identify the mechanism by which LF r-TMS of the
      pre-SMA effects tremor in patients with ET.

      Hypothesis: Inhibition of the pre-SMA by LF r-TMS improves tremor in ET by normalizing
      pre-SMA output, and improving motor control, as determined shortening of the delay in the
      second agonist burst, seen in ET patients. At conclusion of this study expect to have
      sufficient pilot data to justify larger pivotal trials designed to establish the efficacy of
      pre-SMA r-TMS in ET.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean TRS (Tremor Rating Score)</measure>
    <time_frame>Baseline (Visit 2) post intervention</time_frame>
    <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean TRS (Tremor Rating Score) at 4 Week Followup</measure>
    <time_frame>4 week followup(visit 18)</time_frame>
    <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean TRS (Tremor Rating Score) at 8 Week Followup</measure>
    <time_frame>8 week followup (visit 19)</time_frame>
    <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean TRS (Tremor Rating Score) at 12 Week Followup</measure>
    <time_frame>12-week followup(visit 20)</time_frame>
    <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Active pre-SMA rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham pre-SMA rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil</intervention_name>
    <description>Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.
Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.</description>
    <arm_group_label>Active pre-SMA rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eSHAM system</intervention_name>
    <description>implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)</description>
    <arm_group_label>Sham pre-SMA rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 of age

          -  Meet the diagnostic criteria for essential tremor with visible upper limb tremor

          -  Must be either on stable medications to treat tremor for 30 days, or no medications to
             treat tremor

        Exclusion Criteria:

          -  History of seizures

          -  History of chronic pain conditions

          -  Any metal in their body above their shoulders

          -  Use of medications that lower seizure threshold including:

               -  broad classes of drugs such as tricyclic antidepressants

               -  anti-psychotics

               -  neuroeptics

               -  thyroid medications and stimulants

          -  Use of any medications that cause tremor, Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <results_first_submitted>July 13, 2018</results_first_submitted>
  <results_first_submitted_qc>February 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>clinic</recruitment_details>
      <pre_assignment_details>screening procedures per inclusion and exclusion criteria, no wash out, stayed on meds.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Active pre-SMA rTMS</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>sham tms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>active tms</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>sham tms</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.6" spread="12.17"/>
                    <measurement group_id="B2" value="71.6" spread="12.17"/>
                    <measurement group_id="B3" value="71.6" spread="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean TRS at Baseline Visit</title>
          <description>TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="8.276"/>
                    <measurement group_id="B2" value="34" spread="5.385"/>
                    <measurement group_id="B3" value="35" spread="6.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean TRS (Tremor Rating Score)</title>
        <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
        <time_frame>Baseline (Visit 2) post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
          </group>
          <group group_id="O2">
            <title>Sham</title>
          </group>
        </group_list>
        <measure>
          <title>Mean TRS (Tremor Rating Score)</title>
          <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="7.701"/>
                    <measurement group_id="O2" value="27.6" spread="8.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean TRS (Tremor Rating Score) at 4 Week Followup</title>
        <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
        <time_frame>4 week followup(visit 18)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
          </group>
          <group group_id="O2">
            <title>Sham</title>
          </group>
        </group_list>
        <measure>
          <title>Mean TRS (Tremor Rating Score) at 4 Week Followup</title>
          <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.60" spread="9.555"/>
                    <measurement group_id="O2" value="29.2" spread="5.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean TRS (Tremor Rating Score) at 8 Week Followup</title>
        <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
        <time_frame>8 week followup (visit 19)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Pre-SMA rTMS</title>
          </group>
          <group group_id="O2">
            <title>Sham Pre-SMA rTMS</title>
            <description>The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil: Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.
Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.
eSHAM system: implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean TRS (Tremor Rating Score) at 8 Week Followup</title>
          <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="9.555"/>
                    <measurement group_id="O2" value="29.6" spread="5.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean TRS (Tremor Rating Score) at 12 Week Followup</title>
        <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
        <time_frame>12-week followup(visit 20)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
          </group>
          <group group_id="O2">
            <title>Sham</title>
          </group>
        </group_list>
        <measure>
          <title>Mean TRS (Tremor Rating Score) at 12 Week Followup</title>
          <description>Participants will be videotaped as they are being examined for the purpose of rating their tremor for the TRS. TRS scale is a range of 0 - 84 (0 being the least severe and 84 being the most severe tremor)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="7.294"/>
                    <measurement group_id="O2" value="29.6" spread="8.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Pre-SMA rTMS</title>
          <description>The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil: Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.
Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.</description>
        </group>
        <group group_id="E2">
          <title>Sham Pre-SMA rTMS</title>
          <description>The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil: Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.
Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.
eSHAM system: implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gonzalo REvuelta</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-7262</phone>
      <email>revuelta@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

